Author: Sara E. Bass
Sulindac, a non-steroidal anti-inflammatory drug, as well as its metabolites, sulindac sulfide (sulfide) and sulindac sulfone (sulfone) have demonstrated chemopreventive capabilities against several types of cancer, most notably reducing the incidence and mortality of colorectal cancer. The biochemical mechanism underlying these effects remains unresolved, however. Sulindac has been shown to inhibit
polycyclic aromatic hydrocarbon-induced tumorigenesis in various rodent models.
Polycyclic aromatic hydrocarbons are detoxified by a series of enzymes that are primarily under the control of the aryl hydrocarbon receptor (AhR). We therefore hypothesized that modulation of the activity and…
